Agios Pharmaceuticals, Inc. cash flow to debt ratio of -927.64% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Agios Pharmaceuticals, Inc.'s free cash flow has increased -3.64% from $-391.53M last year to $-377.29M, signaling increasing performance

Agios Pharmaceuticals, Inc.'s debt to equity ratio is 0.03, which means that the company's assets are healthy financed, signaling financial stability.

Agios Pharmaceuticals, Inc.'s debt has decreased relative to shareholder equity from 0.04 last year to 0.03 today, signaling strengthened financials

Agios Pharmaceuticals, Inc. has a net cash position, so leverage is healthy.

Agios Pharmaceuticals, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Agios Pharmaceuticals, Inc.'s profit margin has decreased (122.66%) in the last year from 1.85K% to -418.24%, signaling decreasing performance

Agios Pharmaceuticals, Inc.'s short-term assets of $942.05M exceed its short-term liabilities of $82.21M

Agios Pharmaceuticals, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Agios Pharmaceuticals, Inc.'s return on equity of -35.67%, is lower than 15.00%, indicating bad performance

Agios Pharmaceuticals, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Agios Pharmaceuticals, Inc. had positive net income in only 2 out of 5 years, indicating unstable earnings

Agios Pharmaceuticals, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Agios Pharmaceuticals, Inc. has negative free cash flow, indicating cash burn

Agios Pharmaceuticals, Inc.'s yearly earnings has decreased 161.27% since last year from $673.73M to $-412.78M, signaling decreasing performance

Agios Pharmaceuticals, Inc.'s yearly revenue has increased 48.03% since last year from $36.50M to $54.03M, signaling increasing performance

ROIC -43.30% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Agios Pharmaceuticals, Inc.'s 3-year revenue CAGR of 55.97% is positive, indicating growing revenue over the past 3 years

Agios Pharmaceuticals, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Agios Pharmaceuticals, Inc. had positive ROE in only 2 out of 5 years, indicating inconsistent returns on equity

Agios Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Agios Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Agios Pharmaceuticals, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Agios Pharmaceuticals, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Agios Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Agios Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Agios Pharmaceuticals, Inc. has a price-to-book ratio of 1.89x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Agios Pharmaceuticals, Inc. has a price-to-sales ratio of 19.72x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue